Business Segments Perspective Therapeutics, Inc.

Stocks

Real-time Estimate Cboe BZX Other stock markets 11:32:56 08/07/2026 pm IST			5-day change	1st Jan Change
3.395 ^USD	-0.73%		-2.17%	+23.09%

03/06	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort	MT
03/06	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI

Breakdown by Business Segment (USD)

Fiscal Period: December	2021	2022	2023	2024	2025
Biological Products
Radiopharmaceutical development	-	-	14.34L	14.54L	9L
Total Assets	-	-	9.79Cr	34Cr	27Cr
Interest Expense	-	-	-84T	-48T	-4L
Income Tax Expense	-	-	-26.51L	-20.97L	-8L
CAPEX	-	-	-10.72L	-5.44Cr	-1.27Cr
EBT	-	-	-4.01Cr	-8.04Cr	-10Cr
Gross Profit	-	-	14.34L	-	-
D&A	-	-	10L	22.99L	32.44L
Operating Income	-	-	-4.09Cr	-9.09Cr	-11Cr
Net Income	-	-	-4.65Cr	-7.93Cr	-10Cr
Isotope-Based Medical Devices	1.01Cr	1.08Cr	-	-	-
Total Assets	7.04Cr	6.44Cr	-	-	-
Interest Expense	-	-	-	-	-
CAPEX	-4L	-3L	-	-	-
EBT	-33.87L	-72.72L	-	-	-
Gross Profit	51.21L	46.16L	-	-	-
D&A	2L	3L	-	-	-
Operating Income	-34.46L	-73.91L	-	-	-
Net Income	-33.87L	-72.72L	-	-	-

Geographical breakdown of sales (USD)

Fiscal Period: December	2021	2022	2023	2024	2025
United States	1Cr	1.08Cr	14.34L	14.54L	9L
Total Assets	7.04Cr	6.44Cr	9.79Cr	34Cr	27Cr
Interest Expense	-	-	-84T	-48T	-4L
Income Tax Expense	-	-	-26.51L	-20.97L	-8L
D&A	-	-	10L	22.99L	32.44L
CAPEX	-	-	-10.72L	-5.44Cr	-1.27Cr
Gross Profit	-	-	14.34L	-	-
Net Income	-	-	-4.65Cr	-7.93Cr	-10Cr
EBT	-	-	-4.01Cr	-8.04Cr	-10Cr
Operating Income	-	-	-4.09Cr	-9.09Cr	-11Cr
Non - United States	5.03T	-	-	-	-